UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Emplo ...

InspireMD, Inc. (NASDAQ:NSPR) Q4 2020 Earnings Conference Call March 9, 2021 8:30 AM ET Company Participants Scott Gordon - President, Core IR, Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the InspireMD Year End 2020 Financial Results and Corporate Update Conference Call. At this time, all participan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) [X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of incorporation or organization) 4 Men ...

InspireMD, Inc. (NASDAQ:NSPR) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants Scott Gordon - President, Core IR, Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Benjamin Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to InspireMD Third Quarter 2020 Financial Results and Corporate Update Conference Call. At this time, all partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other juris ...

Financial Data and Key Metrics Changes - For Q2 2020, total revenue was $313,000, a decrease from $1.354 million in Q2 2019, representing a 77% decline [18][26] - For the first half of 2020, total revenue was $1.347 million compared to $1.769 million for the same period in 2019, indicating a 24% decrease [18] - The net loss for Q2 2020 was $2.48 million or $0.20 per share, compared to a net loss of $2.206 million or $1.59 per share in Q2 2019 [30] Business Line Data and Key Metrics Changes - Sales volume of CGuard EPS decreased by 76% from $1.1 million in Q2 2019 to $300,000 in Q2 2020 [26][27] - Sales volume of MGuard EPS fell by 82% from $238,000 in Q2 2019 to $42,000 in Q2 2020 [28] - Gross margin decreased to -38.3% in Q2 2020 from 32.6% in Q2 2019 [29] Market Data and Key Metrics Changes - The company is seeing a resurgence of elective procedures in key markets, particularly in Italy, Spain, and Germany [18] - Brazil's healthcare market is expected to reach $1.8 billion with a CAGR of 9% through 2023, representing a significant opportunity for expansion [10] Company Strategy and Development Direction - The company aims to convert vascular surgeons to adopt carotid artery stenting as a standard of care, similar to other vascular conditions [21] - Plans to expand into growth markets in South America and the Asia-Pacific region are ongoing, with Brazil being a key focus [18][24] - The company is pursuing both standard and special reimbursement pathways in France to expedite market entry [38] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the adverse impact of COVID-19 on elective procedures but remains optimistic about recovery as healthcare systems adapt [7][19] - The company is focused on operational efficiency and cost reduction to navigate the challenges posed by the pandemic [8][20] - Management believes that the technology represents a significant advancement in treating carotid artery disease and is optimistic about future growth [19] Other Important Information - The company completed an equity financing raise of $11.5 million to support its operations during challenging times [9] - The FDA granted conditional approval for the Investigational Device Exemption (IDE) application to initiate a pivotal study of CGuard EPS [15][16] Q&A Session Summary Question: What is the plan regarding launching in Brazil and the timeline? - The groundwork is in place for launching CGuard in Brazil, with contracts established and preparations made for market entry [33][36] Question: Can you explain the dual pathway for reimbursement in France? - The company is pursuing both standard and special reimbursement pathways, with the standard expected to be quicker, while the special may take 9-12 months [37][39] Question: What has historically held back carotid stenting from becoming more prevalent? - Early generation carotid stents did not perform as expected compared to open surgical procedures, which has affected adoption rates [44] Question: What advancements are being made in peri-procedural devices? - The company is exploring various options for peri-procedural devices to enhance the CGuard offering and broaden its portfolio [51]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number: 001-35731 InspireMD, Inc. 4 Menorat Hamaor St. [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdiction of (I.R.S. ...

InspireMD, Inc. (NASDAQ:NSPR) Q1 2020 Earnings Conference Call May 12, 2020 8:30 AM ET Company Participants Jeremy Feffer - Investor Relations Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Operator Greetings and welcome to the InspireMD First Quarter 2020 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2123838 (State or other jurisdict ...

InspireMD, Inc. (NASDAQ:NSPR) Q4 2019 Earnings Conference Call March 10, 2020 8:30 AM ET Company Participants Jeremy Feffer ??? Investor Relations Marvin Slosman ??? Chief Executive Officer Craig Shore ??? Chief Financial Officer Conference Call Participants Vernon Bernardino ??? H.C. Wainright Operator Greetings, and welcome to the InspireMD Fourth Quarter 2019 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operat ...